Boothbay Fund Management, LLC Biotechnology

Boothbay Fund Management, LLC

$3.6 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
INCY Incyte Corp	$15.7B	$299,000 0.01% of portfolio	4,534	Q3 2024 New
ITOS I Teos Therapeutics, Inc.	$276M	$290,000 0.01% of portfolio	28,468	Q3 2024 Added 55.84%
UTHR United Therapeutics Corp	$16.6B	$290,000 0.01% of portfolio	810	Q3 2024 New
INVA Innoviva, Inc.	$1.2B	$280,000 0.01% of portfolio	14,547	Q3 2024 New
AMLX Amylyx Pharmaceuticals, Inc.	$205M	$276,000 0.01% of portfolio	85,477	Q2 2024 Reduced 16.83%
ELYM Eliem Therapeutics, Inc.	$109M	$273,000 0.01% of portfolio	53,674	Q3 2024 Added 74.78%
FOLD Amicus Therapeutics, Inc.	$2.53B	$265,000 0.01% of portfolio	24,857	Q3 2024 New
ACAD Acadia Pharmaceuticals Inc	$2.79B	$264,000 0.01% of portfolio	17,157	Q3 2024 New
MDXG Mimedx Group, Inc.	$983M	$257,000 0.01% of portfolio	43,519	Q3 2024 New
VCEL Vericel Corp	$2.81B	$252,000 0.01% of portfolio	5,969	Q3 2024 New
IFRX Infla Rx N.V.	$107M	$241,000 0.01% of portfolio	158,035	Q1 2024 Added 11.57%
VERV Verve Therapeutics, Inc.	$331M	$240,000 0.01% of portfolio	49,724	Q3 2024 New
AVTE Aerovate Therapeutics, Inc.	$62.3M	$204,000 0.01% of portfolio	97,842	Q3 2024 Reduced 11.33%
VERU Veru Inc.	$62.5M	$203,000 0.01% of portfolio	264,067	Q1 2024 New
PRQR Pro Qr Therapeutics N.V.	$183M	$194,000 0.01% of portfolio	106,703	Q1 2024 Added 11.44%
LYEL Lyell Immunopharma, Inc.	$149M	$193,000 0.01% of portfolio	139,880	Q2 2024 New
ALLK Allakos Inc.	$82.2M	$171,000 0.0% of portfolio	264,102	Q2 2024 Added 4.2%
KZR Kezar Life Sciences, Inc.	$445M	$160,000 0.0% of portfolio	208,985	Q3 2024 Added 38.87%
ABOS Acumen Pharmaceuticals, Inc.	$66.8M	$128,000 0.0% of portfolio	51,708	Q3 2024 Reduced 39.49%
VTYX Ventyx Biosciences, Inc.	$118M	$119,000 0.0% of portfolio	55,028	Q3 2024 Reduced 56.48%
ELEV Elevation Oncology, Inc.	$16.5M	$110,000 0.0% of portfolio	183,493	Q2 2024 Added 366.0%
SNSE Sensei Biotherapeutics, Inc.	$16M	$103,000 0.0% of portfolio	172,835	Q2 2024 New
XERS Xeris Biopharma Holdings, Inc.	$462M	$98,000 0.0% of portfolio	34,710	Q2 2024 Reduced 19.65%
RAPT Rapt Therapeutics, Inc.	$39.1M	$90,000 0.0% of portfolio	45,050	Q1 2024 New
LRMR Larimar Therapeutics, Inc.	$157M	$89,000 0.0% of portfolio	13,733	Q3 2024 Reduced 81.91%
VNDA Vanda Pharmaceuticals Inc.	$260M	$81,000 0.0% of portfolio	17,344	Q3 2024 New
FULC Fulcrum Therapeutics, Inc.	$227M	$78,000 0.0% of portfolio	21,937	Q3 2024 New
MGNX Macrogenics Inc	$195M	$77,000 0.0% of portfolio	23,520	Q3 2024 Reduced 59.97%
KPTI Karyopharm Therapeutics Inc.	$57.5M	$75,000 0.0% of portfolio	91,091	Q1 2024 Added 11.45%
VYGR Voyager Therapeutics, Inc.	$211M	$71,000 0.0% of portfolio	12,235	Q2 2024 Reduced 69.12%
LYRA Lyra Therapeutics, Inc.	$6.37M	$60,000 0.0% of portfolio	232,670	Q1 2024 Reduced 6.91%
NUVB Nuvation Bio Inc.	$604M	$48,000 0.0% of portfolio	20,885	Q3 2024 Reduced 76.76%
MIST Milestone Pharmaceuticals Inc.	$62.4M	$46,000 0.0% of portfolio	30,779	Q1 2024 Added 11.57%
CMMB Chemomab Therapeutics Ltd.	$24.2M	$41,000 0.0% of portfolio	26,529	Q1 2023 Reduced 48.6%
ANEB Anebulo Pharmaceuticals, Inc.	$37.4M	$36,000 0.0% of portfolio	18,978	Q3 2023 Added 9.58%
TPST Tempest Therapeutics, Inc.	$9.59M	$34,000 0.0% of portfolio	24,572	Q4 2023 New
TARA Protara Therapeutics, Inc.	$65.5M	$31,000 0.0% of portfolio	17,398	Q3 2024 Reduced 13.83%
CHRS Coherus Bio Sciences, Inc.	$114M	$21,000 0.0% of portfolio	20,218	Q2 2024 Reduced 4.92%
DRMAW Dermata Therapeutics Inc Wt Ex	$0	$0 0.0% of portfolio	12,000	Q3 2021 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.